The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: A historical cohort analysis of a generic COX-2 selective inhibitor

John J. Warner, Rick A. Weideman, Kevin C. Kelly, Emmanouil S. Brilakis, Subhash Banerjee, Francesca Cunningham, William V. Harford, Salahuddin Kazi, Bertis B. Little, Byron Cryer

Research output: Contribution to journalArticle

10 Scopus citations


Background: This study compares the risk of acute myocardial infarction among patients exposed to etodolac, naproxen, celecoxib, and rofecoxib. Methods: A retrospective cohort study in 38 258 veteran patients (26 376 patient-years) measured the adjusted odds ratios of acute myocardial infarction during exposure to etodolac, naproxen, celecoxib, or rofecoxib. Results: Diagnosis of acute myocardial infarction was confirmed in 100 patients who were exposed to a study nonsteroidal anti-inflammatory drug. Compared to naproxen, the increased risk of acute myocardial infarction was not significant for etodolac (OR = 1.32, P =.27), whereas celecoxib (OR = 2.18, 95% CI 1.09-4.35, P =.03) and rofecoxib (OR = 2.16, 95 CI 1.04-4.46, P =.04) were significant. A post hoc analysis indicates that patients with a prior history of acute myocardial infarction had a significant, 4.26-fold risk for another acute myocardial infarction if taking celecoxib or rofecoxib. Conclusion: Etodolac is not associated with a statistically increased risk of acute myocardial infarction compared to naproxen.

Original languageEnglish (US)
Pages (from-to)252-260
Number of pages9
JournalJournal of Cardiovascular Pharmacology and Therapeutics
Issue number4
Publication statusPublished - Dec 2008



  • AMI
  • Celecoxib
  • Cohort
  • COX-2
  • Epidemiology
  • Etodolac
  • Naproxen
  • Rofecoxib

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this